Sign in or create an account to add this stock to your watchlist.
About Assembly Biosciences (NASDAQ:ASMB)
Assembly Biosciences, Inc. operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States. It is involved in the development of core protein allosteric modulators that modulate the HBV core protein at various points in the viral lifecycle. The company also develops microbiome program, a platform that includes the identification and selection process to strain isolation and growth under current good manufacturing practice conditions; and a patent pending delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. In addition, it engages in the development of product candidates for various disease indications, such as ulcerative colitis, Crohn's disease, irritable bowel syndrome, non-alcoholic steatohepatitis, immuno-oncology, and clostridium difficile infections by using its microbiome platform. It has a collaboration agreement with Allergan Pharmaceuticals International Limited for the development and commercialization of selected microbiome gastrointestinal programs. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in Carmel, Indiana.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:ASMB
CUSIP92282210
Phone317-210-9311
Debt
Debt-to-Equity RatioN/A
Current Ratio9.30
Quick Ratio9.30
Price-To-Earnings
Trailing P/E Ratio-17.16
Forward P/E Ratio-12.10
P/E GrowthN/A
Sales & Book Value
Annual Sales$9.02 million
Price / Sales94.02
Cash FlowN/A
Price / CashN/A
Book Value$4.98 per share
Price / Book8.29
Profitability
EPS (Most Recent Fiscal Year)($2.41)
Net Income$-42,800,000.00
Net Margins-379.22%
Return on Equity-56.56%
Return on Assets-32.21%
Miscellaneous
Employees79
Outstanding Shares20,550,000
Assembly Biosciences (NASDAQ:ASMB) Frequently Asked Questions
What is Assembly Biosciences' stock symbol?
Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB."
How were Assembly Biosciences' earnings last quarter?
Assembly Biosciences (NASDAQ:ASMB) announced its quarterly earnings data on Monday, May, 7th. The biopharmaceutical company reported ($0.80) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.69) by $0.12. The biopharmaceutical company had revenue of $3.57 million for the quarter, compared to analyst estimates of $1.88 million. Assembly Biosciences had a negative return on equity of 56.56% and a negative net margin of 379.22%. View Assembly Biosciences' Earnings History.
What price target have analysts set for ASMB?
3 equities research analysts have issued 1-year price targets for Assembly Biosciences' shares. Their forecasts range from $45.00 to $75.00. On average, they anticipate Assembly Biosciences' stock price to reach $56.6667 in the next year. View Analyst Ratings for Assembly Biosciences.
Who are some of Assembly Biosciences' key competitors?
Some companies that are related to Assembly Biosciences include Array Biopharma (ARRY), Ultragenyx Pharmaceutical (RARE), Amicus Therapeutics (FOLD), Supernus Pharmaceuticals (SUPN), Ascendis Pharma (ASND), Tesaro (TSRO), Ironwood Pharmaceuticals (IRWD), Portola Pharmaceuticals (PTLA), Clovis Oncology (CLVS), Emergent BioSolutions (EBS), Horizon Pharma (HZNP), Evotec A.G. (EVTCY), Global Blood Therapeutics (GBT), The Medicines (MDCO) and Arena Pharmaceuticals (ARNA).
Who are Assembly Biosciences' key executives?
Assembly Biosciences' management team includes the folowing people:
- Mr. Derek A. Small, Co-Founder, Pres, CEO & Director (Age 42)
- Dr. Richard J. Colonno Ph.D., Chief Scientific Officer (Age 68)
- Mr. Thomas E. Rollins, Exec. Officer (Age 62)
- Mr. David J. Barrett CPA, Strategic Advisor Role (Age 42)
- Dr. Miguel S. Barbosa Ph.D., Strategic Advisor (Age 60)
Has Assembly Biosciences been receiving favorable news coverage?
Media coverage about ASMB stock has trended somewhat negative on Thursday, Accern Sentiment Analysis reports. The research group rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Assembly Biosciences earned a coverage optimism score of -0.12 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 47.88 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are Assembly Biosciences' major shareholders?
Assembly Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include venBio Select Advisor LLC (5.32%), Rock Springs Capital Management LP (2.16%), Northern Trust Corp (1.09%), Lyon Street Capital LLC (0.68%), Victory Capital Management Inc. (0.60%) and JPMorgan Chase & Co. (0.53%). View Institutional Ownership Trends for Assembly Biosciences.
Which institutional investors are selling Assembly Biosciences stock?
ASMB stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, BNP Paribas Arbitrage SA, JPMorgan Chase & Co., A.R.T. Advisors LLC, Hsbc Holdings PLC, Rock Springs Capital Management LP, California Public Employees Retirement System and Dimensional Fund Advisors LP. View Insider Buying and Selling for Assembly Biosciences.
Which institutional investors are buying Assembly Biosciences stock?
ASMB stock was acquired by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Allianz Asset Management GmbH, Allianz Asset Management GmbH, venBio Select Advisor LLC, WINTON GROUP Ltd, Iguana Healthcare Management LLC, Lyon Street Capital LLC and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Assembly Biosciences.
How do I buy shares of Assembly Biosciences?
Shares of ASMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Assembly Biosciences' stock price today?
One share of ASMB stock can currently be purchased for approximately $41.27.
How big of a company is Assembly Biosciences?
Assembly Biosciences has a market capitalization of $836.83 million and generates $9.02 million in revenue each year. The biopharmaceutical company earns $-42,800,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Assembly Biosciences employs 79 workers across the globe.
How can I contact Assembly Biosciences?
Assembly Biosciences' mailing address is 11711 NORTH MERIDIAN STREET SUITE 310, CARMEL IN, 46032. The biopharmaceutical company can be reached via phone at 317-210-9311 or via email at [email protected]
MarketBeat Community Rating for Assembly Biosciences (ASMB)
MarketBeat's community ratings are surveys of what our community members think about Assembly Biosciences and other stocks. Vote "Outperform" if you believe ASMB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASMB will underperform the S&P 500 over the long term. You may vote once every thirty days.
Assembly Biosciences (NASDAQ:ASMB) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Assembly Biosciences in the last 12 months. Their average twelve-month price target is $56.6667, suggesting that the stock has a possible upside of 37.31%. The high price target for ASMB is $75.00 and the low price target for ASMB is $45.00. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Buy | Buy |
| Consensus Rating Score: | 2.33 | 2.33 | 2.67 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $56.6667 | $53.3333 | $40.00 | $42.50 |
| Price Target Upside: | 37.31% upside | 9.81% upside | 10.93% downside | 31.09% upside |
Assembly Biosciences (NASDAQ:ASMB) Consensus Price Target History
Assembly Biosciences (NASDAQ:ASMB) Analyst Ratings History
Show:
(Data available from 5/24/2016 forward)
Assembly Biosciences (NASDAQ:ASMB) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Assembly Biosciences (NASDAQ ASMB) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 18.20%
Institutional Ownership Percentage: 77.35%
Assembly Biosciences (NASDAQ ASMB) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/1/2018 | William R Ringo | Director | Sell | 1,000 | $43.06 | $43,060.00 | 20,465 |  |
| 4/2/2018 | William R Ringo | Director | Sell | 1,000 | $49.32 | $49,320.00 | 20,465 | |
| 3/1/2018 | William R Ringo | Director | Sell | 1,000 | $56.37 | $56,370.00 | | |
| 2/1/2018 | William R Ringo | Director | Sell | 1,000 | $46.86 | $46,860.00 | | |
| 1/2/2018 | William R Ringo | Director | Sell | 1,000 | $45.04 | $45,040.00 | | |
| 12/1/2017 | William R Ringo | Director | Sell | 1,000 | $49.37 | $49,370.00 | 20,465 | |
| 11/1/2017 | William R Ringo | Director | Sell | 1,000 | $29.55 | $29,550.00 | | |
| 10/16/2017 | William R Ringo | Director | Sell | 1,000 | $33.70 | $33,700.00 | | |
| 2/11/2016 | Derek A. Small | CEO | Buy | 10,000 | $5.53 | $55,300.00 | 634,391 | |
| 5/27/2014 | Russell H Ellison | CEO | Buy | 13,000 | $0.92 | $11,960.00 | | |
| 5/23/2014 | David Jonathan Barrett | CFO | Buy | 6,980 | $0.86 | $6,002.80 | | |
| 5/23/2014 | Russell H Ellison | CEO | Buy | 20,000 | $0.91 | $18,200.00 | | |
| 5/21/2014 | Russell Ellison | CEO | Buy | 10,000 | $0.87 | $8,700.00 | 25,000 | |
| 5/20/2014 | David Jonathan Barrett | CFO | Buy | 40,000 | $0.88 | $35,200.00 | 40,000 | |
| 2/5/2013 | Russell H Ellison | CEO | Buy | 15,000 | $2.55 | $38,250.00 | | |
(Data available from 1/1/2013 forward)
Assembly Biosciences (NASDAQ ASMB) News Headlines
| Source: |
|
Assembly Biosciences (NASDAQ:ASMB) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Assembly Biosciences (NASDAQ:ASMB) Income Statement, Balance Sheet and Cash Flow Statement
Assembly Biosciences (NASDAQ ASMB) Stock Chart for Thursday, May, 24, 2018
Loading chart…
